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ABSTRACT

Miller, Taylor Elaine. M.S. Department of Biochemistry and Molecular Biology, Wright
State University, 2017. A novel molecular relationship between PARN and PLD that,
when deregulated, contributes to the aggressive phenotype of breast cancer cell lines.
The removal of mRNA transcript poly(A) tails by 3'-5' exonucleases is the ratelimiting step for controlled mRNA decay in eukaryotes. Poly(A)-specific ribonuclease
(PARN) is one such exonuclease that degrades poly(A) tails, and although its in vitro
activity is well-characterized, PARN’s patho-physiological roles in the cell are not well
understood. Prior studies have found a possible role for PARN in cancer, in that PARN
expression levels in human breast cancer tissues are often decreased compared to normal
control tissues. Indeed, data mined from the ONCOMINE cancer array database showed
that PARN is downregulated in patient invasive breast carcinoma samples compared to
adjacent normal control tissue. Interestingly, phospholipase D (PLD), a cell-signaling
molecule well known for promoting breast cancer cell growth, proliferation, and
metastasis, was upregulated in these same breast carcinoma samples. PARN is known to
target mRNA containing AU-rich elements (AREs) for degradation and although not
identified in the literature as a target of PARN, PLD1 has large AREs in its 3' UTR.
Taken together, as the levels of PLD are elevated in breast cancer and PARN levels are
decreased and PLD1 contains AREs that PARN may directly target, we hypothesized that
a regulatory connection between PARN and PLD would exist. We investigated whether
PARN regulates PLD and if PLD regulates PARN. In non-cancerous cell lines, such as in
COS-7 and HMEC, we found that PARN downregulated the expression of both
predominant mammalian isoforms of PLD, PLD1 and PLD2. This phenomenon was not
observed in the breast cancer cell lines. We also investigated whether the converse was
true, if PLD has any regulatory effect on PARN. We found that PLD and its catalytic
product, phosphatidic acid (PA) in the exogenous form of dioleoyl-PA (DOPA),
increased PARN expression and activity. PARN also co-localized with exogenouslyadded fluorescent PA in cells, as demonstrated by microscopy. However, DOPA did not
bind to recombinant PARN protein in vitro (although PA species with saturated acyl
chains did bind to PARN), suggesting that the effect of DOPA on regulating PARN
iii

expression and activity is most likely through signaling downstream of PA. We
hypothesized that the mechanism by which PARN downregulates PLD in non-cancerous
cells would be absent or inhibited in breast cancer cell lines. We determined that PARN
directly targets the AU-rich 3' UTR of PLD1 that initiates PLD1 mRNA degradation
presumably through PARN deadenylation of the mRNA poly(A) tail. Furthermore, this
effect was largely dependent on the presence of a miR-203 targeting site that immediately
precedes a specific AU-rich element (ARE) in the 3' UTR of PLD1. Thus, a combination
of PARN deadenylase activity and a putative presence of miR-203 synergizes in
destabilizing PLD1 transcripts hampering translation. We found that this newly
discovered mechanism of PLD regulation was absent in the highly aggressive MDA-MB231 breast cancer cell line, which may explain the high expression of PLD in this and
other breast cancer cell lines. We report herein the novel regulatory relationship between
PARN and PLD that, when deregulated, contributes to the phenotype seen in the MDAMB-231 breast cancer cell line.
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I. INTRODUCTION

mRNA Decay
The rates and balance of translation and mRNA decay are important factors for
determining the quantity of protein expressed in the cell. Imbalance between these two
processes can lead to either an overabundance of certain proteins (if translation occurs
faster than mRNA decay) or the opposite case when mRNA decay occurs faster than
translation. The shortening of eukaryotic poly (A) mRNA tails by 3' to 5' exonuclease is
the rate limiting step of mRNA decay (Figure 1) and one of the most potent ways to
repress mRNA translation and to induce transcript turnover (Funakoshi et al., 2007;
Mitchell and Tollervey, 2000; Nousch et al., 2013; Wolf and Passmore, 2014).
Adenylation and deadenylation control mRNA stability and thus gene expression
necessary for not only basic cellular functions, such as development and cell
differentiation, but also in the altered gene expression found in pathological conditions,
such as chronic inflammation, cancer, and abnormal DNA damage response (Jalkanen et
al., 2014; Mazan-Mamczarz et al., 2003; Zhang et al., 2015; Zhang et al., 2010). The two
major eukaryotic deadenylases are the CCR4-NOT transcriptional regulatory complex
and the PAN complex. A third deadenylase, poly(A)-specific ribonuclease (PARN), also
degrades poly(A) tails from the 3' end (Korner et al., 1998; Mian, 1997; Moser et al.,
1997); however, its functional roles and regulation in vivo are not well-characterized.

PARN
PARN is a divalent metal (Mg2+) ion-dependent, poly(A)-specific, processive, 5’
GTP cap-interacting 3’ exonuclease (Martinez et al., 2000). Structurally, PARN consists
of three distinct catalytic exonuclease sites within a nuclease domain, as well as two
RNA-binding domains, termed the R3H and RNA recognition motifs (RRM) (Figure 2).
While all domains have some degree of RNA binding capability, the R3H domain is most
important for PARN dimer formation and stability, while the RRM domain influences 5’
GTP cap binding and PARN processivity (He and Yan, 2014). PARN functions in
mRNA decay by cleaving poly(A) tails to yield adenosine monophosphate (AMP), which
continues mRNA degradation in the 3' to 5' direction (Martinez et al., 2000). This
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deadenylase not only prefers poly(A) compared to poly(U) , poly(G), and poly(C), it also
has been characterized as having a preference for mRNAs that have stretches of AU-rich
elements (AREs) in their 3' UTRs (Helfer et al., 2012; Korner and Wahle, 1997; Lai et
al., 2003; Lin et al., 2007).

Physiological Role of PARN
Within the last two decades, rare autosomal recessive mutations in PARN
resulting in PARN deficiency are involved in the development of severe forms of
dyskeratosis congenita (DC), an inherited telomere disease characterized by shortened
telomeres and a variety of disease phenotypes (Mason and Bessler, 2015; Stuart et al.,
2015; Tummala et al., 2015). This is thought to be caused mainly due to the decrease in
mature human telomerase RNA component (TERC), as PARN is essential in cleaving
oligo(A) tails from immature TERC, thus preventing TERC's degradation in the nucleus.
Telomerase cannot function properly in the absence of mature TERC and progressive
shortening of telomeres results (Moon et al., 2015; Shukla et al., 2016).
PARN targets a group of transcripts that code for cell migration and adhesion
factors and also transcripts involved in p53, FAK and ERK/MAPK signaling, Fcɣ
receptor-mediated phagocytosis and BRCA1 DNA damage response (Devany et al.,
2013; Lee et al., 2012). PARN is involved in the degradation of the oncogenic
microRNA, miR-21-CA, allowing PTEN and p53 to function properly as tumor
suppressors (Boele et al., 2014; Buiting et al., 1999; Copeland and Wormington, 2001).
PARN can directly regulate the stability of transcripts for the oncogenes c-myc, c-fos,
and c-jun. Its deadenylase activity ensures low levels of these mRNAs under normal
conditions (Cevher et al., 2010; Devany et al., 2013; Maragozidis et al., 2012; Moraes et
al., 2006). In addition, PARN overexpression in patient samples of squamous cell lung
carcinoma (SCC) correlated with a significantly increased survival rate (Maragozidis et
al., 2015). Taken together, these findings indicate a tumor suppressor-like function for
PARN. As different types of cancers display variation in PARN expression, it is currently
not well understood why PARN expression and/or activity becomes aberrant in cancer.

2

miRs
MicroRNA (miRNA, miR) are small (~22 nucleotide long) non-coding RNA
molecules. After a series of maturation steps in the nucleus and cytoplasm, mature
miRNA associate with proteins of the RISC (RNA Induced Silencing Complex). The
miRNA loaded into the RISC will then bind to the miRNA compatible sequence in the 3'
UTR (untranslated region) of a target mRNA. This association of the RISC and mRNA
leads to inhibition of protein translation either by inhibiting ribosomal function or by
inducing the degradation of mRNA (Figure 3).

miR-dependent PARN Targeting of mRNAs
PARN physically associates with Ago2 in the RISC (Zhang et al., 2015).
Furthermore, PARN targeting of TP53 mRNA is dependent on the presence of TP53's
ARE in its 3' UTR, as well as miR-504/miR-125b- targeting sites adjacent to the ARE.
MicroRNA-125b-loaded RISC recruits PARN to TP53 mRNA causing subsequent TP53
transcript degradation (Devany et al., 2013; Zhang et al., 2015). The study by (Zhang et
al., 2015) is so far the only published work showing that PARN acts via this mechanism,
although this miR-mediated mechanism has also been demonstrated with other
deadenylases, such as CAF1/CCR4/NOT1 and Pan2-Pan3 (Zhang et al., 2010).

PLD
Phospholipase D (PLD) is a membrane protein important for not only the
structural integrity of cellular membranes but also for its role in cellular signaling through
protein-protein interactions or through its product of enzymatic reaction, phosphatidic
acid (PA) (Gomez-Cambronero, 2014). Although there are several isoforms of PLD, the
most studied are PLD1 and PLD2. PLD hydrolyzes phosphatidylcholine (PC) into its
lipid second messenger, PA, and also choline (Figure 4) (Wang et al., 1994).

Physiological Role of PLD
Pathways that are regulated by PLD have been extensively studied and cover vast
pathways, such as apoptosis, autophagy, exocytosis, endocytosis, Golgi-ER trafficking,
cell proliferation, and cell migration (Frohman, 2015). While important for maintaining
3

normal cell functions, both PLD1 and PLD2 are implicated in a variety of disease states
with cancer being of main concern. Specifically, PLD1 has a role in controlling cell
polarity, cell survival, and cell migration (Bruntz et al., 2014; Cheol Son et al., 2013; Ye
et al., 2013; Zhong et al., 2003), while PLD2 overexpression is connected to breast
cancer cell growth, proliferation, and metastasis and is a known cancer survival signal
(Foster, 2004; Hatton et al., 2015; Henkels et al., 2013; Hui et al., 2006; Rodrik et al.,
2005; Shi et al., 2007). The PA produced in PLD hydrolysis reactions is also highly
mitogenic and is involved in chemotaxis and cell growth (Gomez-Cambronero, 2014).
Currently, what controls the expression of PLD1 and PLD2 and why they are
overexpressed in breast cancer are currently still unknown.

PLD and miRs
It has been shown that miRs 203a, 3619–5p, and 887–5p regulate PLD2
expression in MDA-MB-231 (highly aggressive breast cancer) and miR-203 can also
regulate PLD2 in the U251 glioblastoma cell line (Chen et al., 2014; Fite et al., 2016; Fite
and Gomez-Cambronero, 2016). Overexpression of these aforementioned miRs decreased
not only the expression of PLD2 but also the invasiveness of the MDA-MB-231 cells.
Conversely, exogenously added PA stimulated the expression of these same miRs (Fite et
al., 2016; Fite and Gomez-Cambronero, 2016). Using TargetScanHuman bioinformatics
analysis, miR-203 is predicted to target PLD1, which is currently unverified in the
literature. It is worth considering the fact that the PLD1 3' UTR has many possible AUrich elements (AREs), one of which directly flanks the predicted miR-203 targeting site
(Figure 5). It is possible that PARN may directly target PLD1 mRNA through this large
ARE, and this mechanism may be miR-dependent (miR-203 specifically), as described
earlier herein.

Preliminary Data
Before proceeding with any experiments, we wanted to first confirm that PLD
gene expression is upregulated in human breast tumor samples by establishing the
endogenous levels of PARN gene expression in these same samples. Using the Finak
Breast dataset from the ONCOMINE cancer microarray database (Finak et al., 2008), we
4

determined that PARN was downregulated in invasive breast carcinoma stroma compared
to adjacent non-cancerous breast stroma (Figure 6A), while gene expression of both
PLD1 (Figure 6B) and PLD2 (Figure 6C) were significantly upregulated in the same
dataset. These data suggest that PARN downregulation allowed upregulation of posttranscriptional events normally kept under its control, which could contribute to cancer
development and progression in which PLD1 and PLD2 have already been implicated
(Henkels et al., 2013; Kang et al., 2009; Kang et al., 2015; Park and Min do, 2011).

Hypothesis and Specific Aims
Based on the current available literature, we have identified several gaps in
knowledge. First, the regulation of PLD1and PLD2 is still at present poorly understood
especially in the context of normal versus cancerous breast cells. It is unknown why PLD
becomes or is maintained in an upregulated state in breast cancer. Second, regulation of
PARN expression and also PARN's role in cancer are almost completely undefined, while
no studies have focused solely on elucidating a clear role for PARN in cancers. Third, the
direct mRNA targets of PARN as well as the mechanism by which PARN regulates these
mRNA are poorly characterized. The miR-dependent mechanism by which PARN can
regulate some of its ARE containing mRNAs remains controversial and understudied.
Taken together with our preliminary data, we hypothesized that PARN regulates PLD1
and PLD2 expression under normal conditions and that this regulation could be
attenuated in breast cancer cells. This hypothesis was tested in two distinct aims: 1.) To
validate the regulatory relationship between PLD and PARN expression in a normal and
breast cancer cell line; and 2.) To identify the mechanism by which PARN regulates PLD
expression in normal versus breast cancer cell lines.

5

Figure 1. Deadenylation-dependent mRNA decay 3’-5’. An schematic illustrating the
order of events in eukaryotic deadenylase-dependent mRNA decay with emphasis on
PARN. Garneau et al. The highways and byways of mRNA decay. Nature Reviews
Molecular Cell Biology 8; 113-126 (February 2007).
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Figure 2. Basic PARN structure. PARN contains nuclease domains that carry out its
exonuclease function (through 3 distinct exonuclease sites) as well as two RNA-binding
domains, the R3H and RNA-recognition motifs (RRM).

7

Figure 3. MicroRNA mRNA post-transcriptional regulation mechanism schematic.
After exportation from the nucleus and further processing into mature microRNA in the
cytoplasm, microRNA are loaded into the RNA-Induced Silencing Complex (RISC). The
microRNA then facilitates the interaction between a complimentary sequenced target
mRNA and the RISC to either 1.) cause the mRNA’s degradation or 2.) repress translation
through blockage of the ribosome resulting in less target mRNA translation into protein.

8

Figure 4. Reaction Scheme of PLD. PLD1 and PLD2 both hydrolyze
Phosphatidylcholine (PC) into Phosphatidic Acid (PA) and free Choline. Rouzer, C.A.
Targeting Flu Through a Host Protein. VICB Communications. August 20, 2014 .
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Figure 5. PLD1 3’ UTR ARE and miR-203 targeting site. The predicted miR-203
targeting site (ACAUUUCA) is colored red, while the adjacent ARE is colored orange.
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Figure 6. PLD and PARN are differentially expressed in invasive breast carcinoma
versus adjacent non-cancerous tissue. Analysis of PARN (A), PLD1 (B), and PLD2 (C)
gene expression in human invasive breast carcinomas versus normal adjacent tissue using
microarray data from the Finak Breast Dataset.
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II. MATERIALS AND METHODS

Materials
Rabbit PLD2 (N-term) (Abgent Cat#: AP14669a, San Diego, CA), mouse PLD1
(F-12) (Santa Cruz Cat#: sc-28314), rabbit Pierce PARN (Thermo Scientific Cat#: PA530252, Pittsburgh, PA), rabbit beta-actin (Cell Signaling Cat#: 4970S, Danvers, MA),
HRP-linked rabbit IgG (Cell Signaling Cat#: 7074S, Danvers, MA), and HRP-linked
mouse IgG (Cell Signaling Cat#: 7076S, Danvers, MA) antibodies were used for western
blots. For immunofluorescent microscopy, goat PARN (N-12) (Cat#: sc-47618) and
donkey anti-goat IgG-R (Cat#: sc-2094) were purchased from Santa C'ruz Biotechnology
(Dallas, TX). Antibodies were validated by the manufacturer. 1,2-dioleoyl-sn-3phosphate (dioleolyl-PA; DOPA) (Cat#: 840875), 1,2-diarachidonyl-sn-glycero-3phosphate (AraPA) (Cat#: 840886), 1,2-dimyristoyl-sn-glycero-3-phosphate (DMPA)
(Cat#: 830845), 1,2-dilauroyl-sn-glycero-3-phosphate (DLPA) (Cat#: 840635), 1-oleoylsn-glycero-2,3-cyclic-phosphate (Lyso-PA) (Cat#: 857328), 1,2-dioctanoyl-sn-glycero-3phosphocholine (PC) (Cat#: 850315), L-a-Phosphatidylinositol-4,5-bisphosphate (PIP2)
(Cat#: 840046), and 1-oleoyl-2-(6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]hexanoyl)sn-glycero-3-phosphate (NBD-PA) (Cat#: 810175) were purchased from Avanti Polar
Lipids (Alabaster, AL). Transit 2020 transfection reagent was from Mirus Bio (Madison,
WI). ECL western blotting reagents were from GE Healthcare (Piscataway, NJ). QPCR
reagents and enzymes were from Fisher Scientific/Life Technologies (Pittsburgh, PA).
Plasmid DNAs used herein were as follows: pcDNA3.1-myc-PLD2-WT and
pcDNA3.10-myc-PLD2-K758R were previously designed in our lab, pCMV6-mycDDK-PARN-WT was from Origene (Cat#: RC207220, Rockville, MD) and this plasmid
was the basis for site-directed mutagenesis to generate PARN-H377A. DharmaFECT 2
transfection reagent was purchased from Dharmacon/GE Healthcare (Cat#: T-2002-03).
Ambion single siRNA were purchased from ThermoFisher Scientific (Pittsburgh, PA)
and were as follows: 5 nM PARN siRNA (Cat#: AM16708 ID#: 11661), 5 nM PAN2
siRNA (Cat#:AM16708A ID#: 105177), and 50 µM Negative Control siRNA (Cat#:
AM4611). Pooled siRNA were purchased from Santa Cruz Biotechnology (Dallas, TX)
and were as follows: 10 µM PARN siRNA (Cat#: sc-61297) and 10 µM control siRNA-A
12

(Cat#: sc-37007). Recombinant purified PARN (Cat#: TP307220) and PAN2
(Cat#:TP300573) were purchased from Origene. Dharmacon miRIDIAN Mimic Human
hsa-miR-203a-3p (Cat#: C-300562-03) and miRIDIAN microRNA Mimic Negative
Control #1 (Cat#: CN-001000-01-50) were purchased from GE Healthcare. The miR
plasmids were both tagged to the GFP coding sequence. The empty vector negative
control and miR-203 miExpress Precursor miRNA Expression Clone plasmids were from
GeneCopoeia (Rockville, MD Cat #: HmiR0249-M04-B). The PLD1 and PLD2 3' UTR
luciferase vectors were purchased from SwitchGear Genomics/Active Motif. Essential
components purchased specifically for RNA IP were torula yeast RNA (Chem-Impex
Int'l Inc. Cat#: 01625, Wood Dale, IL), polyuridylic acid potassium salt (MP Biomedicals
Cat#: 102707, Solon, OH), ribonucleoside vanadyl complex (VRC) (New England
BioLabs Cat#:S1402S), and QIAshredder columns (QIAGEN Cat#: 79654, Hilden,
Germany).

Cell Culture
COS-7, MCF-7, and MDA-MB-231 cells were obtained from ATCC (Manassas,
VA, USA). This repository has indicated that the cell lines were recently authenticated
and tested negative for contamination. Human Mammary Epithelial cells (HMEC) and
mammary epithelial cell growth media containing BPE, hEGF, hydrocortisone, GA-1000
and insulin were from Cell Applications, Inc. (San Diego, CA, USA). HMECs were
cultured in TPP growth factor-treated flasks (Cat#:90075) and 6-well plates
(Cat#:92406). COS-7, MCF-7, MDA-MB-231 cells were cultured in HyClone
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal
bovine serum (FBS). All cells were maintained at 37 °C in an incubator with a humidified
atmosphere of 5% CO2.

ONCOMINE
Using the ONCOMINE cancer microarray database (www.oncomine.org) as an
integrated data-mining tool, we compared the gene expression profiles of PARN and
PLD2 in 49 human breast cancer stroma samples contrasted against 6 healthy breast
stroma samples. We mined the Finak Breast dataset (Finak et al., 2008) that analyzed
13

subtypes of tumor stroma corresponding to good- and poor-outcome breast cancers from
invasive breast cancer patients

Dioleoyl-PA/ NBD-PA treatment
“Super-Stock” 1 mM dioleoyl-PA was prepared with 1 mg of 1,2-dioleoyl-sn-3phosphate, or NBD-PA, in 1.4 mL of “Super-Stock Buffer” consisting of 50 mg of Fatty
Acid-free BSA per 10 mL of 1x PBS, pH 7.2. Dioleoyl-PA is a cell permeable form of
phosphatidic acid (PA) (Lehman et al., 2007). This “Super-Stock” dioleoyl-PA was then
sonicated on ice 2x 4 s each with a 4 s pause in between sonications. “Intermediate 100
µM liposomes” were then made using 25 µl of the “Super-Stock” dioleoyl-PA and 225 µl
of Cell Starvation Media (DMEM + 0.1% bovine serum albumin), which were then used
to prepare the final concentration of 30 nM (unless otherwise indicated by the figure
legends) dioleoyl-PA used to incubate cells for the indicated times in various figures.

Cell Transfection: Overexpression
Cells were plated into 6-well plates in complete media and allowed to grow 12-24
h before transfection. The PLD2 plasmid used codes for the entire gene including the 3'
UTR, while the PLD1 plasmid excludes the 3' UTR. All PLD and PARN overexpression
transfections were accomplished using 2 µg of PLD1 or PLD2 plasmid and/or 1 µg of
PARN plasmid, 300 µl Opti-Mem Serum-Free media, and 2 µl of Transit 2020
transfection reagent per 1 µg DNA. miR plasmid overexpression reactions consisted of 2
µg miR-203 mimic, 300 µl Opti-Mem Serum-Free media, and 2 µl of Transit 2020
transfection reagent per 1 µg DNA. miR mimic transfection reactions for luciferase
assays consisted of 50 nM concentrations of miR-203 mimic, adequate Opti-MEM
serum-free media, and the appropriate volume of DharmaFECT 2 transfection reagent
based on the cell line (COS-7) and number of cells seeded per well (100,000) as
recommended by the manufacturer. All reactions were incubated at room temperature for
20 min before being added drop-wise to the corresponding cells growing in complete
media. Cells were then incubated at 37 °C in an incubator with a humidified atmosphere
of 5% CO2 for 24 h. Media was aspirated and fresh complete media added and cells
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allowed another 24 h of growth in the incubator before harvesting.

Cell Transfection: Silencing
Cells were plated into 6-well plates in complete media and allowed to grow 12-24
h before transfection. Both the single and pooled (3 siRNA each) PARN, PAN2, and
negative control siRNAs purchased were diluted with the manufacturer’s included
nuclease free water to a stock concentration of 50 µM. These siRNA solutions were then
further diluted to 150 nM (yields 50 nM concentration for each siRNA contained within
the pooled siRNAs) for use in all silencing experiments. Equal concentration of negative
control siRNA was used in the negative control siRNA transfections. The siRNA
reactions consisted of siRNA, 300 µl Opti-Mem Serum-Free media, and 5 µl
DharmaFECT 2 transfection reagent. All reactions were incubated at room temperature
for 20 min before being added drop-wise to the corresponding cells growing in complete
media. Cells were then incubated at 37 °C in an incubator with a humidified atmosphere
of 5% CO2 for 24 h. Media was aspirated and fresh complete media added and cells
allowed another 24 h of growth in the incubator before adding a booster of siRNA. Cells
were harvested the next day.

Quantitative Real time PCR (qRT-PCR)
Total RNA was isolated from cells with the RNeasy minikit. RNA concentrations
were quantified using the NanoDrop ND-1000 UV/Vis spectrophotometer and samples
were normalized to 2 µg RNA. Reverse transcription was performed with 2 µg RNA, 210
ng random hexamers, 500 µM dNTPs, 84 units RNaseOUT, and 210 units of
SuperscriptII reverse transcriptase and incubated at 42°C for 55 minutes. qRT-PCR
reactions were run with 100 ng total input RNA, 1 µl (which contained 250 nM of the
probe and 900 nM of the primers) of either FAM-labeled PARN (Hs00377733_m1 Cat#:
4331182) and/or FAM-labeled PLD2 (Hs01093219_m1 Cat#: 4351372) and/or PLD1
(Hs00160118 Cat#: 4331182) gene expression assay multiplexed with the FAM-labeled
housekeeping genes Actin (Hs01060665_g1 Cat#: 4331182), GAPDH (Hs02758991_g1
Cat#: 4331182), and TATA-Binding protein (Hs00427621_m1 Cat#: 4331182). qRTPCR conditions for the Stratagene Mx3000P were: 95°C for 3 min and then 40 cycles of
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the next 3 steps: 30 s at 95°C, 1 min at 60°C, and then 1 min at 72°C. The “cycle
threshold” Ct values were arbitrarily chosen from the linear part of the PCR amplification
curve where an increase in fluorescence can be detected >10 S.E.M. above the
background signal. ΔCt was calculated as: ΔCt = Avg. PLD Ct – Avg. Housekeeping Ct;
and gene fold expression, as 2-(ΔΔCt) = 2-(experimental Condition ΔCt – Control ΔCt).

miR expression measurement by Quantitative Real time PCR (qRT-PCR).
The TaqMan microRNA Cells-to-CT kit (catalog no. 4391848; Life
Technologies) was used to prepare these cell lysates according to the manufacturer’s
protocol. RNA concentrations were determined using a NanoDrop, and samples were
normalized to 60 ng/μl RNA. Reverse transcription was performed in a 15-μl reaction
volume with 1 μg of RNA, 1.5 μl 10X RT buffer, 1 mM dNTPs, 3.8 units of RNase
inhibitor, and 1 μl of Multiscribe reverse transcriptase, and the mixture was incubated in
one cycle at 16°C for 30 min, 42°C for 30 min, and then 85°C for 5 min. Quantitative
PCRs were run in a 20-µl reaction volume using 10 µl TaqMan master mix, 100 ng of
total input RNA, and 1 µl of the relevant microRNA gene expression assay (FAM
labeled) multiplexed with the housekeeping gene (U6). TaqMan miRNA primers and
fluorescent probes were from Life Technologies. Quantitative PCR conditions for the
Stratagene Cycler were 95°C for 10 min and then 50 cycles of the next 3 steps, i.e., 15 s
at 95°C, 1 min at 55°C, and then 30 s at 72°C. The CT values were chosen from the
linear part of the PCR amplification curve, where an increase in fluorescence can be
detected at >10 standard errors (SE) above the background signal. ΔCT was calculated as
follows: ΔCT = avg PLD CT - avg housekeeping CT. The gene expression fold change
was calculated as 2-ΔΔCT = 2(-experimental condition ΔCT - control ΔCT).

SDS-PAGE/Western Blotting
COS-7, HMEC, MCF-7, and MDA-MB-231 cells were transfected as described
previously in this materials and methods section with expression plasmids that are
defined in the figure legends. Cell media was aspirated from the plates and cells washed
2x gently with 1x PBS. Cells were then lifted from the plates by incubation with the
addition of 1 ml trypsin for no more than 5 min, collected into 1.5 ml conical snap-cap
16

tubes, and sedimented at 14000 rpm 4°C for 1 min. The supernatant was aspirated to
waste and cell pellets were resuspended in Special Lysis Buffer (5mM HEPES, 1 µM
leupeptin, 768 nM aprotinin, 100 µM sodium orthovanadate and 0.4% Triton X-100)
(SLB). After sonication of the lysates, samples were resolved using SDS–PAGE and
transferred to a PVDF membrane, followed by immunoblot analysis. Primary antibodies
used were as follows: anti-PARN (1:2000 dilution), anti-PLD1 (1:500 dilution), antiPLD2 (1:500 dilution), and anti-actin (dilution 1:3000), which was used as the equal
protein loading control. Secondary antibodies used were anti-rabbit or anti-mouse
conjugated to horseradish peroxidase (HRP) (1:3000 dilution). Results were visualized
using ECL reagents.

Coomassie Staining
Approximately, 100 ng of purified recombinant PARN and PAN2 protein were
electrophoresed on gels using a conventional SDS-PAGE protocol. The gel was then
rinsed 3 times for 5 min each in purified DI water then incubated overnight in 20 mL of
GelCodeTM Blue Safe Protein Stain (Thermo Scientific, Cat #: 1860983) with gentle
shaking. The gel was then destained using multiple distilled water rinses until the water
remained colorless and the background of the stained gel was reduced to minimal
staining.

Immunofluorescence microscopy
COS-7 cells were seeded onto sterilized glass coverslips placed in the bottom of
6-well plates and allowed 24 h to adhere. Cells were incubated for 30 min in 30 nM
fluorescent NBD-PA. Media was aspirated from the cells and then gently rinsed 1x with
1x PBS. Cells were then fixed onto their coverslips using 4% paraformaldehyde for 10
min at room temperature. The cells were then permeabilized with 0.5% Triton X-100 in
PBS for 10 min at room temp and then incubated in IF blocking buffer (10% fetal calf
serum (FCS), 0.1% Triton X-100, and 1X PBS) for 1 h at room temp. Endogenous
expression of PARN was detected in samples using a 1:200 dilution of PARN anti-goat
antibody in IF blocking buffer for 1 h at room temperature, followed by washing 3x in
1X PBS, and further room temperature incubation with a 1:200 dilution of TRITC17

conjugated donkey anti-goat secondary antibody blocking buffer for 1 h. After washing
3x in 1X PBS, nuclei were stained using a 1:2000 dilution of 4,6-diamidino-2phenylindole (DAPI) in 1X PBS for 5 min at room temp. Coverslips were washed again
3x in 1X PBS and 1x in distilled autoclaved water. Coverslips were then mounted onto
clean glass microscope slides using VectaShield mounting medium (Vector Laboratories
Cat#: H-1000, Burlingame, CA), and cells were visualized using a Nikon 50 Eclipse
epifluorescence microscope.

Lipid-Protein Overlay Assay
The method for preparing and detecting protein-lipid binding has previously been
described (Dowler et al., 2002). In brief, lipids from Avanti Polar Lipids (Alabaster, AL,
USA) were spotted onto a PVDF membrane. Lipids were dissolved in a 2.0:1.0:0.8 ratio
solution of MeOH:CHCl3:H2O. Appropriate amounts of lipid were spotted onto the
membrane. The membrane was blocked overnight with a 3% fatty acid–free BSA
solution. The membrane was then incubated overnight with recombinant PARN protein.
After protein incubation, the membrane was incubated overnight with PARN primary
antibody and was then incubated with rabbit secondary antibody, which was detected
using ECL reagents.

Luciferase Assay
Luciferase reporter assays were performed using the ActiveMotif LightSwitch
Luciferase Assay kit (Cat #: 32031). The reporter vectors contained PLD1 or PLD2 3′
UTR region and a downstream RenSP luciferase region. The PLD1 3' UTR luciferase
plasmid was the basis for site-directed mutagenesis (performed by Mutagenex, Suwanee,
GA) to generate five ARE mutants. Cells were transfected or co-transfected as previously
described with either a miR mimic or plasmid DNA and a LightSwitch PLD1 3' UTR
vector, PLD2 3′ UTR vector, or PLD1 3' UTR mutant construct in a 96-well plate for 36
h. LightSwitch Luciferase Assay Reagent was added to the wells, and the signal was
measured on a luminometer. The luciferase signal for each condition was calculated and
normalized to the negative control.
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Mutant Luciferase Constructs
To investigate the importance of the miR-203 targeting site and ARE of interest in
the 3' UTR of PLD1 for PARN targeting, five new mutant PLD1 3' UTR plasmids were
created (Figure 7). The LightSwitch PLD1 3' UTR plasmid was used as the basis for sitedirected mutagenesis to generate these new mutants. One substitution mutant, PLD1 3'
UTR mutMIR, had the miR-203 ACAUUUCA targeting site at bp 3021 to 3028 of the
full plasmid mutated to UGUAAAGU to disrupt miR-203 binding. Four deletion mutants
were also created. PLD1 3' UTR ΔMIR had the entire miR-203 ACAUUUCA targeting
site deleted (bp 3021 to 3029 of the full plasmid). PLD1 3' UTR Δ1/3ARE had
approximately 1/3 of the ARE of interest deleted (bp 3550 to 3813 of the full plasmid).
PLD1 3' UTR Δ2/3ARE had approximately 2/3 of the ARE of interest deleted (bp 3290
to 3813 of the full plasmid). PLD1 3' UTR ΔARE had the entire ARE of interest deleted
(bp 3030 to 3813 of the full plasmid).

RNA IP
The RNA IP protocol was based on (Conrad, 2008) (Figure 8). COS-7, HMEC,
MCF-7, and MDA-MB-231 cells were plated in 6-well plates and grown to confluency.
Plates were then placed on ice and media replaced with ice cold 1X PBS and cells fixed
via 250 mJ/cm2 UV irradiation using the Stratalinker UV Crosslinker (Model 1800
Cat#:400071). Cells were then scraped with a rubber policeman, collected, pelleted, and
resuspended in 1 mL ice cold 1X PBS. Samples were then centrifuged at 2400 x g for 1
min at 4°C and the supernatant decanted to waste. Approximately, 140 µL of SDS lysis
buffer was added and pellets gently mixed. Samples were then heated in a 65°C water
bath for 5 min and subsequently incubated on ice for 3 min. Approximately, 560 µL of
ice cold RIPA correction buffer was added to each sample and samples passed through
individual QIAshredder spin columns twice by centrifugation at 16,000 x g for 1 min
each. The resulting pellets were sedimented 3 more times at 16,000 x g for 10 min each,
transferring the supernatant to new tubes each time and discarding the pellets.
Approximately, 200 µL of PARN antibody-bound Protein G agarose beads were added to
each sample and rotated at 4°C for 2 h. Beads were allowed to settle out of solution at
room temperature for 5 min and supernatants gently aspirated to waste. Beads were
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resuspended in 400 µL ice-cold RIPA buffer, centrifuged at 850 x g at room temp for 1
min. Beads were allowed to settle out of solution at room temp for 5 min. This RIPA
buffer step was repeated 3 more times for a total of 4 RIPA buffer washes. Beads were
resuspended in 200 μl RIPA buffer, 300 μl Proteinase K solution added, and then placed
in a 37°C water bath for 1.5 h. To this mix, 30 μl of 3 M sodium acetate (pH 5.2), and
350 µL Phenol:chloroform:isoamyl alcohol, 25:24:1 (pH 7.5; PCA) were added, vortexed
for 10 s, and then centrifuged at 16,000 g at room temp for 5 min. The aqueous phase of
each sample was transferred to tubes containing 900 μl of 100% ethanol, incubated on
dry ice for 15 min, and centrifuged at 16,000 x g for 15 min at room temp. Pellets were
washed with 70% ethanol and centrifuged at 16,000 x g for 5 min at room temp. Ethanol
was aspirated from the pellets that were then allowed to air dry. Pellets were resuspended
in 20 µl RNase-free water and 20 µl of 2X DNase solution added. Samples were
incubated at 37°C for 45 min then 180 µl of G-50 buffer, and 200 µl PCA added,
vortexed 10s, and centrifuged at 16,000 x g for 5 min at room temp. The aqueous layer
was transferred to tubes containing 500 μl of 100% ethanol and centrifuged at 16,000 x g
for 15 min at room temp. The ethanol was aspirated and the pellet resuspended in 20μl of
RNase-free water, and the RNA concentration was measured using the NanoDrop.
Samples were then used to backtranscribe cDNA and perform qRT-PCR as described in
these methods.

PLD Activity Assay
Cell lysates were processed for PLD activity in PC8 liposomes and [3H]n-butanol
beginning with the addition of the following reagents (final concentrations): 3.5 mM PC8
phospholipid, 45 mM HEPES (pH 7.8) and 1.0 µCi [3H]n-butanol in a liposome form, to
accomplish the transphosphatidylation reaction of PLD, and were incubated for 20 min at
30 °C with continuous shaking. Reactions were stopped with the addition of 0.3 ml icecold chloroform/methanol (1:2), and lipids were isolated and resolved by thin layer
chromatography. The amount of [3H]-phospho-butanol ([3H]-PBut) that co-migrated
with PBut standards (Rf=0.45–0.50) was measured by scintillation spectrometry.
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PARN Activity Assay
The PARN activity assay was based on (Shyu et al., 1991; Wilson and Treisman,
1988) with some modifications. Cell lysates were treated with 10μl/mL Halt Protease and
Phosphatase Inhibitor Cocktail (Thermo Scientific, Cat #: 78440) and used in
deadenylation reactions of [32P]-ɣATP radiolabeled A15 substrate. The A15 substrate and
poly(A) ladder (A2, A5, A10, A15, and A30 mixed together) were 5' radiolabeled by T4
Polynucleotide Kinase (T4PNK). The positive control was recombinant purified PARN
protein and the negative control was A15 substrate alone. Reaction products were
subjected to autoradiography. Deadenylation is evidenced by a greater mobility of
radiolabeled spots, the appearance of smears versus the negative control of A15 alone, and
a lighter signal. This was quantified with the following formula:
PARN Activity =

Statistical Analysis
Results are expressed as means + Standard Error of the Mean (SEM). The
difference between means was assessed by t-test calculated using GraphPad Prism 6
(GraphPad Software Inc., La Jolla, CA) and P values of <0.05 were taken as significant.
In the figures, the (*) symbols above bars denote statistically significant increases
between samples. The (#) symbols above bars denote statistically significant decreases
between samples.
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Figure 7. Schematic of PLD1 3’ UTR LightSwitch Luciferase plasmid and its
mutants. The luminescent reporter gene (RenSP) is a small Renilla reniformis luciferase
protein that lacks dependence on ATP, unlike firefly luciferase, and produces light at 480
nm. This region is colored green in the schematic above. The miR-203 targeting site
within the 3’ UTR is indicated by a thick blue box (light blue for the mutated site) at 2659
to 2666 bp in each schematic, except for the ΔMIR construct in which the miR-203 site is
deleted. The ARE portion of the 3’ UTR is colored orange and is progressively shorter in
each of the three ARE mutants. Δ1/3ARE has the last third of the ARE removed.
Δ2/3ARE has the last two-thirds of the ARE removed. ΔARE has the entire ARE
removed up to the miR-203 targeting site.
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Figure 8. Pictorial representation of the RNA I.P. protocol. Plated cells are cross
linked using UV irradiation and then collected. After several treatments with various
buffers and centrifugation, whole cell lysate from these cells is added to Protein G
agarose beads coated with IgG antibody specific for the protein of interest. When the
whole cell lysate is added to these antibody-bound beads, the protein of interest will be
bound to the antibody and pulled out of solution. By the end of the RNA I.P. process,
DNA and protein are degraded, leaving behind only the RNA that was pulled down in
complex with the protein of interest.
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III. RESULTS

Differential expression of PARN, PLD1, and PLD2 in breast cancer cell lines
compared to 'normal' cell lines.
A molecular connection between deadenylases and PLDs has not been
investigated to date. Therefore, we determined the endogenous gene expression of
PARN, PLD1, and PLD2 in COS-7 fibroblasts (one example of a normal cell line) and
HMEC (a non-cancerous human mammary epithelium cell line), as well as in the breast
cancer cell lines MCF-7 (low aggressive) and MDA-MB-231 (highly aggressive). MCF-7
and MDA-MB-231 cells had much higher PLD1 and PLD2 but lower PARN gene
expression compared to the two normal cell lines (Figure 9). This results was also
generally reflected in the protein expression results as well, although with some degree of
variation (Figure 10). The fact that MCF-7 and MDA-MB-231 cells had more PLD
expression than non-cancerous cells was in accordance with previous studies (Fite et al.,
2016; Fite and Gomez-Cambronero, 2016). The observation that MCF-7 and MDA-MB231 cells also had less PARN expression than the non-cancerous cells was in agreement
with the Finak Breast data-mining results (Preliminary Data, Figure 6), and as such, we
moved forward with the investigation of the possible relationship between PLD and
PARN in these cell lines of interest.

PARN negatively regulates PLD2 expression in normal cells and PLD2 positively
regulates PARN.
First, we sought to elucidate the regulatory relationship between PARN and the
PLD2 isoform. When PARN was silenced in the normal cell line (Figure 11A,
quantification B-C), PLD2 protein increased above that of the mock and negative siRNAtransfected cells, while PARN protein decreased. Similar results were observed in
PARN-silenced cancerous MCF-7 cells (Figure 11D, quantification E-F). These results
indicate that PARN has a strong negative regulatory effect on cellular PLD2 levels.
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Figure 9. PLD and PARN are differentially expressed in breast cancer versus noncancerous cell lines. Quantitative RT-PCR results for endogenous gene expression of (A)
PARN, (B) PLD1, and (C) PLD2 in the cell lines of interest: COS-7 (green monkey
kidney fibroblasts), HMEC (non-cancerous human mammary epithelium), MCF-7 (low
aggressive human breast cancer), and MDA-MB-231 (high aggressive human breast
cancer). Results are relative to three housekeeping genes: TBP, GAPDH, and Actin. Error
bars are means + s.e.m. The differences between the means were assessed by t-test.
*P<0.05 **P<0.01 ***P<0.005 and ****P<0.001, significant increase between samples;
#P<0.05, significant decrease between samples.
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Figure 10. PLD and PARN protein expression in the cell lines. Western blot results for
endogenous protein expression of PLD1, PLD2, and PARN in the cell lines of interest.
The PLD1 blots come from two different gels, as many cell lines were run at one time,
therefore this panel is split to show the results of the COS-7 and HMECs, which were run
on the same gel together, as well as the MCF-7 and MDAs, which were run on another
separate gel together. Actin is used as equal protein loading control. Images are
representative of n=4.
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Figure 11. Silencing of PARN increased PLD2 protein expression. Cells were treated
with transfection reagents only (Mock) or silenced with siRNA-negative control (Neg.) or
with siRNA for PARN as indicated. Four days post-transfection, lysates were used for
protein expression analyses. (A-C) Protein expression for COS-7 cells and (D-F) for
MCF-7 cells. Western blots are presented in A and D and the densitometry of PARN and
PLD2 bands are shown in COS-7 cells (B-C) and MCF-7 cells (E-F) relative to their
corresponding Actin. Actin was used as the equal protein loading control. Western blot
images are representative of n=3. Error bars are means + s.e.m. The differences between
means were assessed by t-test. *P<0.05, significant increase between samples and
controls; #P<0.05, significant decrease between samples and controls.
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Differential effects of PARN+PLD2 co-expression in normal cells versus breast
cancer cells.
Since a robust signaling interaction between PARN and PLD2 seems to exist in
cells, we next transfected both types of cells with a combination of expression plasmids
coding for PARN or PLD2 proteins. Co-expression of PARN+PLD2 in COS-7 cells led
to an overabundance of PARN protein expression with a concomitant abrogation in PLD2
protein expression (Figure 12A). This would indicate that in COS-7 cells, PARN is able
to control PLD2 levels to mock level even when PLD2 is overexpressed. Unexpectedly,
in the MCF-7 breast cancer cells, both PARN and PLD2 protein co-overexpression
augmented the expression of each other (Figure 12B), which is completely the opposite
result seen in COS-7 cells. The results of qRT-PCR assays to measure gene expression in
these same conditions are shown for PLD2 in Figure 13A-B and for PARN in Figure
13C-D, and reinforce the protein expression results.
To further validate the co-overexpression results in Figure 12 and 13, we
performed a PLD activity assay in samples treated mock or overexpressed PLD2, PLD2 +
PARN wild-type (WT), or PLD2 + catalytically inactive PARN-H377A. As shown in
Figure 14, similar to the protein and qRT-PCR results, overexpression of PARN-WT with
PLD2 was able to decrease PLD activity compared to the PLD2 overexpressed sample
alone. Of significance is the observation that the catalytically inactive PARN was not
able to reduce PLD2 activity. Since PLD2 levels are naturally high in cancer cells (Hui et
al., 2006; Shi et al., 2007; Zheng et al., 2006), our results indicate that not only is PARN
expression low in breast cancer cells, its ability to seemingly regulate expression of
proteins, such as PLD2, is dysregulated. This phenomenon would be advantageous for a
cancer cell, as PLD2 is implicated in cell invasion and cancer metastasis (Chen et al.,
2012; Henkels et al., 2013; Knoepp et al., 2008).
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Figure 12. PARN overexpression keeps PLD2 protein near Mock expression levels in
COS-7, but not the MCF-7 cell line. (A) Western Blot results for PARN and PLD2
protein expression in COS-7 and (B) MCF-7 cells showing mock transfection alone,
PLD2 overexpressed, PARN overexpressed, or PLD2 + PARN co-overexpressed. Actin
was used as equal protein loading control. Images are representative of n=3.
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Figure 13. PARN co-overexpression with PLD2 partially negates PLD2 gene
overexpression, an effect not seen in the MCF-7 cell line. (A) PLD2 gene expression in
COS-7 and (B) MCF-7 cells with mock transfection alone, PLD2 overexpressed, PARN
overexpressed, or PLD2 + PARN co-overexpressed as measured via qRT-PCR. (C)
PARN gene expression in COS-7 and (D) MCF-7 cells with mock transfection alone,
PLD2 overexpressed, PARN overexpressed, and PLD2 + PARN co-overexpressed as
measured via qRT-PCR. Results are relative to Actin housekeeping gene. Error bars are
means + s.e.m. The difference between means was assessed by t-test. *P<0.05 **P<0.01
and ***P<0.005, significant increase between samples; #P<0.05, significant decrease
between samples.
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Figure 14. Wild-type PARN co-overexpression with PLD2 partially returns PLD
activity to near mock level. PLD activity in COS-7 cells treated with transfection
reagents alone (Mock), PLD2 overexpressed, PLD2 + PARN-WT overexpressed, or
PLD2 + PARN-H377A overexpressed. Error bars are means + s.e.m. The difference
between means was assessed by t-test. *P<0.05, significant increase between samples and
control; #P<0.05 significant decrease between samples.
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PLD2 catalytic activity is required to exert an effect on PARN gene expression.
We next investigated if the catalytic activity of PARN and PLD2 are required to
influence the expression of each other. At least in COS-7, PARN overexpression
decreased PLD2 gene expression. Using the PARN deadenylase-inactive mutant, PARNH377A, we observed that the ectopic expression of this inactive mutant PARN also
decreased expression of PLD2 to a similar degree to that of wild-type PARN, even
though as shown previously in Figure 14, the PARN-H377A mutant does not
significantly alter PLD lipase activity (Figure 15A). This result means that PARN
overexpression decreased PLD2 gene expression independent of PARN’s deadenylase
activity. However, since the PARN-H377A mutant still contains intact RNA-binding
domains, it is possible that PARN could still bind mRNA targets and inhibit their
translation/induce transcript degradation. When we induced overexpression of PLD2, we
observed an upregulation in PARN gene expression that was abolished by overexpression
of the lipase-inactive PLD2-K758R mutant (Figure 15B). Thus, the catalytic activity of
PARN does not seem to be necessary for PLD2 regulation, but the catalytic activity of
PLD2 is necessary for PARN regulation.

Phosphatidic acid increased both PARN and PLD2 protein expression.
As only catalytically active PLD2 had a positive effect on PARN expression
(Figure 15B), we investigated what effect phosphatidic acid, PA (the product of the PLD
reaction), might have on PARN. PA is a strong mitogen and regulator of gene
transcription (Yoon et al., 2015). COS-7 cells were incubated with increasing
concentrations of 1,2-dioleoyl-sn-3-phosphate (dioleoyl-PA) for either 20 min or 4 h. As
shown in Figure 16A-B, both PLD2 and PARN protein expression increased
concomitantly with PA concentration. Quantifications of protein bands are shown in
Figure 16C-F. PLD2 protein expression increased during this 4 h incubation up to a peak
at 100 nM dioleoyl-PA followed by a decrease at higher concentrations of dioleoyl-PA,
while PARN protein increased throughout (Figure 16D,F). A similar effect was seen
during a shorter incubation time (20 min) (Figure 16C,E). These results indicate there is a
concentration dependent threshold to which the cells produce more protein in response to
PA.
32

Figure 15. PLD2 catalytic activity is required to increase PARN gene expression,
while both wild-type and the catalytically inactive PARN decrease PLD2 gene
expression. (A) PLD2 gene expression in COS-7 treated with mock transfection alone or
PLD2-WT or lipase-inactive PLD2-K758R mutant were each overexpressed. (B) PARN
gene expression in COS-7 cells mock transfection alone or PARN-WT or deadenylaseinactive PARN-H377A mutant were each overexpressed and used to measure mRNA
levels via qRT-PCR. Results are relative to Actin housekeeping gene. Error bars are
means + s.e.m. The differences between means were assessed by t-test. *P<0.05,
significant increase between samples; #P<0.05, significant decrease between samples.
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Figure 16. Exogenous dioleoyl-PA increases PARN and PLD2 protein expression.
COS-7 cells were incubated with increasing concentrations of exogenously added
dioleoyl-PA for 20 min (A,C,E) or 4 h (B,D,F). PARN and PLD2 protein expression were
assessed via Western Blot. Results from 20 min dioleoyl-PA treatment are shown in (A),
while results from 4 h dioleoyl-PA treatment are shown in (B). PARN protein
densitometry is graphically represented in (C), for 20 min dioleoyl-PA treatment, and in
(D), for 4 h dioleoyl-PA treatment. PLD2 protein densitometry is graphically represented
in (E), for 20 min dioleoyl-PA treatment, and in (F), for 4 h dioleoyl-PA treatment. Actin
was used as the equal protein loading control. Western blot images are representative of
n=3.
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Exogenous addition of phosphatidic acid to cell cultures enhances PARN
deadenylase activity, as measured in vitro.
We next investigated if PA affects the deadenylase activity of PARN. To
accomplish this goal, we set up a robust and reliable in vitro PARN deadenylase assay to
validate PARN enzymatic activity, as shown in Figure 17-19. In Figure 17, [32P]-γATPradiolabeled A15 RNA substrate was deadenylated by purified recombinant PARN
protein, which has a different mobility in the denaturing gel than that of the boiled
(inactive) purified recombinant PARN protein and the A15 substrate alone. Deadenylation
was evidenced by an increased mobility of radiolabeled and degraded products (the
smeared product) versus the input A15 and boiled PARN negative controls alone. Figure
18A shows that PARN protein but not recombinant, purified PAN2 protein (another
closely related deadenylase) deadenylated the A15 substrate, which suggests the A15
substrate is specific for PARN and not for another deadenylase. Figure 18B depicts a
Coomassie-stained gel that indicates the high purity of the recombinant, purified proteins
used. PARN deadenylase activity was effectively silenced in COS-7 cells with siPARN
RNA (Figure 18C) but not with siPAN2 RNA. This indicates that in our assay conditions,
PAN2 did not contribute to the deadenylase activity found in cell lysates. A further
control for these activity experiments is shown in Figure 19, whereby PARN activity in
lysates from cells overexpressing wild-type PARN increased in a concentrationdependent manner when compared to overexpression of the deadenylase-inactive mutant
PARN-H377A.
After thoroughly validating the PARN activity assay, we wanted to see if
incubating COS-7 cells with dioleoyl-PA would not only increase PARN protein
expression, but also correspondingly increase PARN activity. COS-7 cells incubated with
300 nM PA for 30 min and 30 nM PA for 4 h showed increased PARN activity compared
to the negative control (A15 substrate alone, no lysate) and Mock (no PA treatment)
(Figure 20). These results go hand-in-hand with the protein expression experiment where
PA increased PARN expression. These data indicate PA positively affects PARN
expression and activity in non-cancerous cells. This could be one mechanism by which
COS-7 cells use to respond to upregulation of PLD2 in an attempt to bring cellular PLD2
levels back to normal through upregulation of PARN expression and activity. We
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propose this mechanism is either not present in breast cancer cells or is somehow
dysregulated, which allows the uncontrolled and sustained upregulation of PLD2 in these
cells.

PARN co-localizes with PA-containing vesicles in the cell and directly binds
saturated PA species.
We wanted to determine if the effects of PA on PARN expression and activity are
through direct interaction between PARN protein and the phospholipid itself. No
published studies thus far have investigated a relationship between PARN and any type
of lipid. First, we wanted to determine if PARN protein localizes with PA. To accomplish
this we incubated COS-7 cells for 30 min with 30 nM NBD-PA, a green fluorescently
tagged PA similar in structure to the dioleoyl-PA used in all PA experiments thus far. We
found that this NBD-PA formed distinct punctae and vesicular structures throughout the
cells, but these structures were concentrated near the perinucleus (Figure 21, green
panel). PARN was concentrated inside the nucleus, presumably in the nucleoli, but also
highly concentrated in the same vesicle structures as the NBD-PA (Figure 21, red panel).
When merged, this co-localization of PARN with the NBD-PA vesicles became much
clearer (Figure 21, merged image).
Second, now that we have established that PARN protein comes into spatial
contact with exogenously added PA, we wanted to determine if PARN physically binds
phospholipids. PVDF membrane was spotted with equal concentrations of seven different
phospholipids: 1,2-dioleoyl-sn-3-phosphate (DOPA), 1,2-diarachidonyl-sn-glycero-3phosphate (AraPA), 1,2-dimyristoyl-sn-glycero-3-phosphate (DMPA), 1,2-dilauroyl-snglycero-3-phosphate (DLPA), 1-oleoyl-sn-glycero-2,3-cyclic-phosphate (Lyso-PA), 1,2dioctanoyl-sn-glycero-3-phosphocholine (PC), and L-a-Phosphatidylinositol-4,5bisphosphate (PIP2). This membrane was then incubated with purified PARN protein and
probed with PARN antibody. If PARN protein bound a lipid, PARN antibody would also
bind and allow us to visualize the spots. As shown in Figure 22A, PARN only bound
DMPA, DLPA, and PC (spots 4, 5, and 7 respectively). PARN did not bind the dioleoylPA (DOPA), the PA that closely resembles that of endogenous PA produced by PLD
action. Since this is the PA we have used in our PARN expression and activity
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experiments, this indicates that the effects observed are due to some other downstream
signaling and not direct binding of DOPA to PARN. Figure 22B shows a control blot
spotted with solvent alone or DOPA and there were no further treatments with blocking
buffer or antibodies. This blot was placed in a box to stain the lipid with iodine vapors.
The DOPA spot was stained yellow showing that our lipids bound the paper.

A model of regulation between PLD2/PA and PARN.
A model representing the proposed regulation we have characterized between
PLD2/PA and PARN is represented in Figure 23. The results of this study indicate that
PA, the hydrolysis product of PLD action, enhanced the activation and synthesis of
PARN protein. As illustrated in Figure 23A, when PLD2/PA levels increased in normal
cells, like COS-7, this caused an increase in PARN gene and protein expression, as well
as an increase in its deadenylase activity. This overall elevation in PARN levels in the
cell then decreased PLD2 expression to basal levels. The mechanism by which this
occurs still needs to be fully elucidated, as it is possible that PARN can degrade PLD2
mRNA directly and thus influence PLD2 expression levels, or by a more indirect
mechanism where PARN degrades other mRNA that then affect PLD2 expression. As
illustrated in Figure 23B, the large negative feedback of PARN on PLD expression
appears attenuated in cancer cells, due to not only the inherently low basal PARN
expression, but it also could be due to compromised degradation of target mRNAs or
even a yet to be established regulatory pathway. Taken together these results further
support the significant role of PLD2 and the importance of elucidating its regulation in
breast cancer. This is also the first study to specifically focus on and attempt to discern a
role for PARN in breast cancer and in the PLD regulation process.
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Figure 17. Purified recombinant PARN protein and protein from COS-7 cell lysates
deadenylate A15 substrate. Validation study for in vitro PARN deadenylase activity
assay. Radiolabeled A15 RNA substrate was deadenylated by recombinant PARN with
respect to the A15-only control and inactivated (boiled) recombinant PARN protein.
Deadenylation is evidenced by a greater mobility of radiolabeled spots and the
appearance of smears versus the negative controls of inactivated PARN or A15 alone.
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Figure 18. The PARN activity assay is specific for PARN and not PAN2. Further
validation of the specificity of the PARN deadenylase assay. (A) Recombinant PARN but
not recombinant PAN2 is able to deadenylate A15. (B) Coomassie-stained gel indicating
the high purity of the recombinant, purified proteins used. (C) PARN deadenylase
activity as measured in lysates from COS-7 cells that were silenced with 150 ng of either
control RNA (siNeg), siPARN, or siPAN2.
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Figure 19. The PARN-H377A mutant has decreased PARN activity compared to
PARN-WT. PARN activity in COS-7 cells overexpressing either PARN-WT or -H77A
proteins. Error bars are means + s.e.m. The differences between means were assessed by
t-test. #P<0.05, significant decrease between samples and control.
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Figure 20. Exogenous addition of dioleoyl-PA increases PARN activity above mock
levels. PARN activity of lysates prepared from COS-7 cells incubated with or without
(Mock) the indicated concentrations of dioleoyl-PA for 30 min or 4 h. Error bars are
means + s.e.m. The differences between means were assessed by t-test. *P<0.05,
significant increase between samples; #P<0.05, significant decrease between samples.
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Figure 21. PARN protein co-localizes with NBD-PA containing vesicles. COS-7 cells
were incubated for 30 min in 30 nM fluorescent PA (NBD-PA) and were then used for
immunofluorescence microscopy using TRITC-conjugated PARN IgG antibodies. Image
is representative of sextuplicate fields. Localization of the NBD-PA is in green
(excitation=490 nm; emission=525 nm, using a FITC filter; top left panel), while
localization of PARN is in red (excitation=557 nm; emission=576 nm, using a TRITC
filter; bottom left panel). Nuclei were stained blue with DAPI and the images merged
(right panel). White arrows point to areas of high co-localization (yellow), which
correspond to vesicles localized perinuclear.
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Figure 22. PARN binds saturated PA species but not dioleoyl-PA. (A) Results from a
lipid-overlay assay incubated with purified recombinant PARN protein and probed with
PARN antibody. Samples spotted were as follows: 1) solvent only; 2) DOPA; 3) AraPA;
4) DMPA; 5) DLPA; 6) Lyso-PA; 7) PC; and 8) PIP2. (B) Control blot spotted with
solvent only or DOPA. Blot stained with iodine vapors to show that lipid binds the paper
(yellow spot).
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Figure 23. Proposed model for the interactions of PARN with PLD2 in noncancerous
versus cancerous cells. (A) In non-cancerous cells, a positive and a negative feedback
mechanism exists, whereby PLD2 and PA production initially upregulates PARN gene
and protein expression. This PARN protein then decreases PLD2 expression by
potentially degrading PLD2 mRNA directly, or by degrading other mRNA that affects
PLD2 expression (a more indirect mechanism), bringing PLD2 levels back to a normal
level. (B) Working model for the deregulation between PARN and PLD2 in cancerous
cells. As in non-cancerous cells, PLD2 upregulates PARN. However, PARN cannot
downregulate PLD2. Low basal PARN expression, compromised degradation of mRNA,
or a yet to be established regulatory pathway may all contribute to higher PLD2 protein
expression, which mediates the increased cell growth, proliferation, and invasion of these
cells.
44

We have shown that both PLD1 and PLD2 are overexpressed in human breast
cancer tissue as well as in human breast cancer cell lines, while PARN is downregulated
in these same samples (Figure 6, 9-10). We also established that there is a regulatory
relationship between PLD2 and PARN, not only in terms of gene and protein expression
levels, but also in terms of enzymatic activities, although the exact mechanism behind
this is still not understood. It is well known that PARN targets mRNA containing AUrich elements (AREs) in their 3’ UTR. To see if PLD1 contained such a region, we
searched the sequence of its 3’ UTR and found several stretches of AU-rich regions, one
of which was quite long at the terminus of the 3' UTR (approximately783 nt long) (Figure
5, yellow). This region was also of particular interest to us because immediately
preceding this region was a suspected miR-203 binding site (Figure 5, red). As shown
previously in our lab, miR-203 is capable of targeting PLD2’s 3’ UTR and thus
regulating its protein expression (Fite et al., 2016; Fite and Gomez-Cambronero, 2016).
This same miR is also predicted to target PLD1. Taking these observations into account
during our investigation into PARN regulation of PLD, we shifted our focus to PLD1 as
we believe a direct mechanism for PARN regulation on this PLD does in fact exist. As
the PLD2 3' UTR contains miR targeting sites, miR-203 being one of them, it does not
contain any significantly sized AREs. We thus set out to determine if PARN directly
regulates PLD1 through interaction with the PLD1 3' UTR and whether this was miR203-dependent.

PLD1 gene and protein expression increases in the absence of PARN.
To determine if PARN is having an effect at all on PLD1 expression, we
transiently silenced PARN in all four of our cell lines of interest: COS-7, HMEC, MCF7, and MDA-MB-231. Figure 24 shows significant upregulation of PLD1 gene
expression when PARN was knocked down in the COS-7 (Figure 24A-B), HMEC
(Figure 24C-D) and MCF-7 (Figure 24E-F) cell lines, however this effect was not seen in
the MDA-MB-231 breast cancer cell line even though PARN gene expression was
significantly down-regulated (Figure 24G-H). This indicated that under normal
conditions (COS-7 and HMEC) PARN keeps PLD1 mRNA levels under control. This
phenomenon seems to persist in the pre-EMT low aggressive MCF-7 breast cancer cell
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line, but it is not present to the same degree in the post-EMT highly aggressive MDAMB-231 breast cancer cell line.
PARN directly regulates the PLD1 3’ UTR.
To confirm that PARN protein directly binds and regulates PLD1 expression via
interaction with the PLD1 3’ UTR, we performed a luciferase reporter assay. As shown in
Figure 25, if PARN regulates PLD1 3’UTR expression, then when PARN binds the
PLD1 3’ UTR within the luciferase fusion mRNA, translation will be inhibited and less
luciferase signal will be produced compared to the PARN silenced condition. Indeed,
silencing of PARN in COS-7 cells resulted in an increase in PLD1 3’ UTR luciferase
signal above that of the mock condition (Figure 26A), while the PLD1 3’ UTR luciferase
signal greatly decreased from mock levels when PARN was overexpressed even at all
concentrations tested (Figure 26B). This experiment was repeated with the PLD2 3’ UTR
but yielded a much smaller effect (Figure 26C-D). These results together yield clear
evidence that PARN strongly and directly regulates PLD1 expression through targeting
of the PLD1 3’ UTR, but the same is not true for PARN regulation of the PLD2 3' UTR.
To further support PARN directly binding and regulating PLD1 mRNA, an RNA I.P.
assay was performed with the cell lines of interest. After subjecting these cell lines to UV
cross-linking to more stably bind protein complexes together, cells were collected and
lysates prepared. PARN protein was pulled down using anti-PARN antibody bound to
Protein G agarose beads and anti-IgG was used as a control. Any mRNA physically
associated with PARN protein should also be pulled down (Figure 27, inset cartoon).
After I.P., qRT-PCR was performed to measure the PLD1 mRNA potentially pulled
down along with the PARN protein, which would indicate physical binding of PARN to
that mRNA. COS-7, HMEC, and MCF-7 cell lines showed more PLD1 pulldown in the
PARN I.P. samples compared to their corresponding IgG control (Figure 27). This was
not observed in the MDA-MB-231 cell line, indicating that what PARN protein is present
in these cells may have inhibited PLD1 mRNA binding capability in this aggressive
breast cancer cell line, which might have contributed to the upregulation of PLD1 in this
cell line. Next, we wanted to investigate the potential for this PLD1 regulation to not only
involve PARN but also miR-203 either in a miR-dependent or -independent mechanism.
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Figure 24. PLD1 gene expression increases in the absence of PARN in all cell lines
except for MDA-MB-231. PLD1 and PARN gene expression for COS-7 (A-B), HMEC
(C-D), MCF-7 (E-F), and MDA-MB-231 (G-H) cell lines measured by qRT-PCR relative
to three housekeeping genes: TBP, GAPDH, and Actin. Error bars are means + s.e.m. The
differences between means were assessed by t-test. *P<0.05 and **P<0.01, significant
increase between samples and controls.; ##P<0.01 and ####P<0.0001, significant
decrease between samples and controls.
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Figure 25. Scheme of PLD 3’ UTR luciferase assays. If PARN regulates the PLD
3’UTR expression, then PARN will bind the PLD 3’ UTR within the luciferase fusion
mRNA. If this happens, then translation is inhibited and less luciferase signal is produced
when compared to the PARN silenced condition.

48

Figure 26. PARN directly binds and regulates the PLD1 3’ UTR. (A) Luciferase assay
results from COS-7 cells co-transfected with the PLD1 3’ UTR luciferase reporter
plasmid and either siRNA negative control or siPARN. (B) Luciferase assay results from
COS-7 cells co-transfected with the PLD1 3’ UTR luciferase reporter plasmid and either
transfection reagents alone (Mock) or overexpressed PARN plasmid in the amounts
indicated. (C) Luciferase assay results from COS-7 cells co-transfected with the PLD2 3’
UTR luciferase reporter plasmid and either siRNA negative control or siPARN. (D)
Luciferase assay results from COS-7 cells co-transfected with the PLD2 3’ UTR
luciferase reporter plasmid and either transfection reagents alone (Mock) or
overexpressed PARN plasmid in the amounts indicated. Error bars are means + s.e.m.
The differences between means were assessed by t-test. *P<0.05 and **P<0.01,
significant increase between samples and controls.; #P<0.05 and ####P<0.0001,
significant decrease between samples and controls.
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Figure 27. PARN protein is complexed with PLD1 mRNA in the normal, noncancerous and low invasive breast cancer cell lines and much less so in the highly
aggressive breast cancer cell line MDA-MB-231. PLD1 mRNA pulldown by PARN
antibody compared to IgG control in COS-7, HMEC, MCF-7, MDA-MB-231 via RNA
I.P. as measured by qRT-PCR. The companion Western Blot probed for PARN protein in
the I.P. samples is shown below the graph.
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MiR-203 directly regulates PLD1 gene and protein expression.
To confirm that miR-203 regulates PLD1 expression as predicted by TargetScan,
we overexpressed miR-203 plasmid in MDA-MB-231 cells as we know from previous
work in our lab that these cells have low endogenous levels of miR-203 (Fite et al., 2016;
Fite and Gomez-Cambronero, 2016), but high levels of PLD1 (Figure 9-10). Figure 28A
confirms the overexpression of miR-203 in the miR-203 transfected MDA-MB-231 cells.
As predicted, miR-203 overexpression decreased both PLD1 gene expression (Figure
28B) and protein expression by over half (Figure 28C). When overexpressed with the
PLD1 3’ UTR luciferase plasmid, miR-203 significantly decreased the luciferase signal
compared to scramble mimic control indicating that miR-203 was able to directly bind to
and regulate the PLD1 3’ UTR (Figure 28D). Taken together, these data suggest that
miR-203 regulates PLD1 expression.
PARN regulation of the PLD1 3’ UTR is dependent on the presence of both the ARE
and miR-203 binding site.
We wanted to determine whether PARN regulation of PLD1 is dependent on two
features of the PLD1 3’ UTR: the ARE and the miR-203 targeting site. To accomplish
this goal, we performed mutagenesis of the wild-type PLD1 3’ UTR LightSwitch
luciferase reporter plasmid to create five new mutant plasmids. These mutants are
pictorially represented in Figure 7. One mutant, ΔMIR, had the miR-203 targeting site
completely removed. A second mutant, mutMIR, had the miR-203 targeting site mutated
to disrupt miR-203 binding. The other three mutants are deletion mutants of portions of
the ARE, where the last third of the ARE was removed (Δ1/3ARE), the last two-thirds of
the ARE was removed (Δ2/3ARE), or the entire ARE up to the miR-203 targeting site
was removed (ΔARE).
First we needed to confirm that miR-203 could no longer regulate the mutMIR
and ΔMIR PLD1 3' UTR mutants. As shown in Figure 29A, miR-203 overexpression no
longer decreased luciferase signal in both the mutMIR and ΔMIR validating that these
two mutants had abolished miR-203 binding. The red symbols indicate that these samples
(mutMIR, Δ1/3ARE, Δ2/3ARE, and ΔARE) were significantly increased or decreased
compared to the PLD1 WT 3’ UTR overexpressing miR-203. Next, we either silenced
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PARN or overexpressed PARN in the presence of the mutant PLD1 3' UTR luciferase
constructs. When PARN was silenced, there was an increase in luciferase signal in both
the WT and Δ2/3ARE samples, however, no significant increase in luciferase signal was
observed in the mutMIR, ΔMIR, Δ1/3ARE, or ΔARE samples (Figure 30A). When
PARN was overexpressed, there was a near abolishment in luciferase signal in the WT
samples, whereas luciferase signal decreased to a significantly lesser extent in the
Δ1/3ARE, Δ2/3ARE, and ΔARE samples. The red symbols indicate that these samples
were significantly increased or decreased compared to the PLD1 WT 3’ UTR that were
silenced or overexpressed PARN. Importantly, in corroboration with the PARN silencing
results, no significant decrease in luciferase signal was observed in the mutMIR and
ΔMIR samples indicating that PARN regulation of the PLD1 3' UTR requires the
presence of the intact wild-type miR-203 targeting site strongly suggesting this is a miR203 dependent mechanism (Figure 30B).

Model for PARN regulation of PLD1 expression.
In normal breast cells, such as HMEC (Figure 31A), PARN and miR-203
expression levels are high compared to their levels in breast cancer cells. PARN can
physically associate with Ago2 in the RISC and once the RISC is loaded with miR-203, a
3’ UTR targeted interaction with PLD1 mRNA and this complex occurs leading to PLD1
mRNA degradation. This regulation keeps PLD1 levels tightly under control and at a
“normal” basal level. However, in the highly aggressive breast cancer cell line, such as
MDA-MB-231 (Figure 31B), endogenous levels of miR-203 and PARN are much lower
than in normal breast cells, while PLD1 expression is significantly upregulated. With
little to no miR-203 and/or PARN within these cells, PLD1 protein translation proceeds
in a more uncontrolled manner leading to and/or maintaining upregulated PLD1.
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Figure 28. miR-203 overexpression in MDA-MB-231 breast cancer cell line
decreases PLD1 gene and protein expression through direct binding of the PLD1 3’
UTR. (A) miR-203 gene expression in MDA-MB-231 cells control or miR-203 plasmid
overexpressed as measured via qRT-PCR. (B) PLD1 gene expression in MDA-MB-231
cells control or miR-203 plasmid overexpressed as measured via qRT-PCR. P-value was
close to achieving significance at P=0.057. (C) PLD1 protein expression in MDA-MB231 cells control or miR-203 overexpressed. TBP is used as equal protein loading control.
Densitometry values normalized to TBP and relative to the control are shown. Images are
representative of n=3. (D) Luciferase assay results from COS-7 cells co-transfected with
the PLD1 3’ UTR luciferase reporter plasmid and either scrambled mimic or miR-203
mimic. Error bars are means + s.e.m. The differences between means were assessed by ttest. *P<0.05 and ***P<0.005, significant increase between samples and controls.
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Figure 29. Mutation and/or deletion of the PLD1 3’ UTR miR-203 targeting site
abolishes miR-203 regulation of the 3’ UTR. Luciferase assay results from COS-7 cells
co-transfected with the PLD1 3’ UTR luciferase reporter plasmids and either scrambled
mimic or miR-203 mimic. Error bars are means + s.e.m. The differences between means
were assessed by t-test. *P<0.05 and ***P<0.005, significant increase between samples;
##P<0.01, significant decrease between samples. Red symbols denote significant
increase/decrease compared to PLD1 WT 3’ UTR overexpressing miR-203.
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Figure 30. Mutations in the PLD1 3’ UTR significantly reduce PARN regulation of
the 3’ UTR. (A) Luciferase assay results from COS-7 cells co-transfected with the PLD1
3’ UTR luciferase reporter plasmids and either siRNA negative control or siPARN. (B)
Luciferase assay results from COS-7 cells mock transfected (PLD1 3’ UTR luciferase
reporter plasmids alone) or co-transfected with the PLD1 3’ UTR luciferase reporter
plasmids and PARN plasmid. Error bars are means + s.e.m. The differences between
means were assessed by t-test. **P<0.01, ***P<0.005, ****P<0.001, significant increase
between samples. #P<0.05, ##P<0.01, and ###P<0.005, significant decrease between
samples. Red symbols denote significant increase/decrease compared to PLD1 WT 3’
UTR siPARN (for panel A) or PARN overexpression (for panel B).
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Figure 31. Proposed model for miR-203 dependent-PARN post-transcriptional
regulation of PLD1. (A) In normal breast cells (HMEC), endogenous levels of miR-203
and PARN are relatively high compared to PLD1. PARN can physically associate with
Ago2 in the RISC and once the RISC is loaded with miR-203, a 3’ UTR-targeted
interaction with PLD1 mRNA and this complex occurs leading to PLD1 mRNA
degradation. (B) In the highly aggressive breast cancer cell line MDA-MB-231,
endogenous levels of miR-203 and PARN are much lower than in normal breast cells,
while PLD1 expression is significantly upregulated. With little to no miR-203 and/or
PARN within these cells, PLD1 protein translation occurs in a more uncontrolled manner
leading to and/or maintaining upregulated PLD1.
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IV. DISCUSSION

The relationship between phospholipases and RNases is interwoven in terms of
cellular location and function. Previous studies have linked phospholipase C (PLC) to
RNase activity, which serves as a basis for the possibility of other phospholipases being
involved in RNase activities, such as PLD2/PA. It has been previously determined that
PLD and ribonucleases co-localize in the vacuoles of plants (Matile, 1968). It is well
established that PARN exists both in the cytoplasm and nucleus, whereas PLD2 has been
shown to be in the plasma membrane and cytoplasm and its secondary messenger, PA,
can be found throughout the cell to exert a variety of functions in cell signaling (Hondal
et al., 1997; Kravchuk et al., 2001; Zini et al., 1989). Indeed, while immunofluorescence
microscopy and co-IP techniques have not shown definitive evidence of PARN colocalizing or physically interacting with PLD itself (data not shown), our IF experiments
have indicated that PARN can co-localize with PA inside the cell (Figure 21). Taken
together, the research on PLC and current understanding of the subcellular localization of
PLD2, PA and PARN support the notion that these molecules have ample opportunity to
have a direct and/or indirect interaction with one another.
This work identifies that the phospholipid signaling enzyme PLD2 and its
catalytic product, PA, are a novel route for modulating PARN expression and activity.
We report that a possible inter-regulatory relationship exists, whereby PLD2 affected
PARN gene and protein expression, as well as activity, and vice versa. This mechanism
appears to be modulated differently in non-cancer versus cancer cells. The results shown
here support a potentially important role for PA and PLD2 in PARN-mediated mRNA
decay. It is known that PA can activate transcription factors such as PPARα, so it is
possible that an increase in PA may activate transcription factors that could subsequently
increase PARN transcription. Most critically, we also observed strong regulation of both
PLD1 and PLD2 in non-cancer cells via PARN. While we were not able to elucidate the
exact mechanism by which PARN regulates PLD2, we did find that PARN regulates
PLD1 via interaction with the PLD1 3' UTR. This interaction and regulation is dependent
on the presence of the miR-203 targeting site nearest the 3' terminus of the PLD1 3' UTR,
as well as strongly dependent on the presence of a large AU-rich element (ARE) directly
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flanking this miR-203 site. The PARN-mediated regulation of both PLD1 and PLD2
appears to be impaired or nonexistent in highly aggressive breast cancer cells, such as
MDA-MB-231, indicating a critical function for the interplay between PARN and both
PLD isoforms.
The physiological relevance in the proposed regulation and interactions herein lie
in the observed discrepancies between what occurs in normal or non-cancerous cell lines
and what is occurs in the highly aggressive MDA-MB-231 breast cancer cell line. By
using normal/noncancerous and breast cancer cell lines that were mock-treated or that
overexpressed PARN and/or PLD2, we defined the relationship between PARN and
PLD2 (Figure 12-14). First and foremost, cancer cell lines have increased levels of PLD2
(Figure 9-10) and, therefore, higher levels of PA production (Foster, 2009; Foster et al.,
2014). The product of PLD hydrolysis of membranous PC is almost exclusively
monounsaturated PA (e.g. dioleoyl-PA), and as such, we used exogenously added
dioleoyl-PA in our experiments. We believe that our results are evidence of a negative
feedback mechanism in cells, whereby PLD2 overexpression and also PA positively
affected PARN gene and protein expression, as well as activity, which in turn negatively
affected PLD2 gene and protein expression and activity bringing PLD2 back down to
normal mock level. This negative feedback mechanism between PARN and PLD2 was
observed clearly in our normal cell line, COS-7, but was diminished in our breast cancer
cell line, MCF-7, possibly due to an as-yet-unidentified regulator or pathway that leads to
the attenuation of the large negative feedback of PARN on PLD2 expression. This also
demonstrated that immortalization of COS-7 cells was not sufficient for explaining the
effects seen. Cancer cells having low levels of PARN and/or mechanisms in place to
inhibit PARN action on certain mRNA could potentially maintain a more active pool of
mRNA that facilitate overexpression of proteins like PLD2, which are highly relevant to
tumorigenesis, cell migration and metastasis in breast cancer.
Not only have we begun to characterize a complex regulatory relationship
between PARN and PLD2, we identified and characterized a mechanism by which PARN
regulates PLD1. While there are several papers supporting the existence of a miRdependent mechanism in deadenylases such as CCR4-NOT and the PAN2-PAN3
complexes, only one paper exists that actually shows evidence of this phenomena with
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PARN. The PLD1 3' UTR is AU-rich and therefore there are many regions by which
PARN may interact with the mRNA. Here we chose a large ARE in the 3' terminus of the
3' UTR not only because of its size and proximity to the poly-A tail but also because of
the miR-203 targeting site immediately preceding the region, all of which would yield the
highest probability of the existence of an ARE and miR-dependent mechanism by which
PARN regulates PLD1. While we confirmed the miR-targeting site mutant PLD1 3' UTR
luciferase constructs were not regulated by miR-203, the Δ1/3ARE and Δ2/3ARE
constructs actually increased in luciferase signal with the overexpression of miR-203.
This means there was a decreased ability of miR-203 to bind these two specific
constructs. Although further experimentation would be required to pinpoint the exact
reason for this phenomena, two possible explanations are that miR-203 may require a
certain length ARE to bind properly and/or these two constructs fold in such a way that
excludes miR-203 from its binding site (Hon and Zhang, 2007). PARN regulation of the
PLD1 3' UTR was abolished in the miR-203 targeting site mutants, however a variation
in responses was seen with the three ARE mutants. Between PARN silencing and
overexpression, it was clear that deleting the last third of the 3' UTR was not enough to
abolish PARN regulation, while it did significantly decrease it. Near complete abrogation
of PARN regulation required the deletion of the entire ARE. This is in stark contrast to
the complete abolishment seen with the miR-203 targeting site mutants, indicating that
PARN regulation of the PLD1 3' UTR is most dependent on the presence of the miR-203
targeting site and to at least the first two-thirds of the identified ARE. It is important to
note that COS-7, HMEC, and MCF-7 cell lines have higher levels of miR-203 and PARN
compared to the highly aggressive MDA-MB-231 breast cancer cell line. Because of this,
the proposed miR-203/PARN regulatory mechanism to keep PLD1 levels in check would
be mostly if not completely absent. We propose this mechanism to be at least partially
responsible for the upregulated expression of PLD1 in the MDA-MB-231 breast cancer
cell line although the reason for the low levels of miR and PARN in these cells is not yet
known.
In conclusion, we report here a regulatory relationship between PARN and both
PLD isoforms, which constitutes a new and possibly essential component in posttranscriptional regulation in higher eukaryotes, as well as in disease states such as cancer.
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Further investigation is needed into determining how and why the interaction between
these proteins becomes dysregulated in breast cancer to start developing new methods for
re-establishing normal interaction and remedying or preventing the cancerous pathology.
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